About Redbiotec
Redbiotec is a company based in Schlieren (Switzerland) founded in 2006 by Corinne John. Redbiotec has raised $1.87 million across 2 funding rounds from investors including Redalpine. Redbiotec offers products and services including Key Proteins, Genetic Materials, and BRISPR®tech. Redbiotec operates in a competitive market with competitors including Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Mereo BioPharma, among others.
- Headquarter Schlieren, Switzerland
- Founders Corinne John
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Redbiotec Ag
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$1.87 M (USD)
in 2 rounds
-
Latest Funding Round
$1.45 M (USD), Private Equity Round
Nov 27, 2014
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Redbiotec
Redbiotec offers a comprehensive portfolio of products and services, including Key Proteins, Genetic Materials, and BRISPR®tech.
Proteins for therapeutic and industrial applications
Materials for genetic research and production
Platform for protein and genetic material development
Funding Insights of Redbiotec
Redbiotec has successfully raised a total of $1.87M across 2 strategic funding rounds. The most recent funding activity was a Private Equity Round of $1.45 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Redbiotec
Redbiotec has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Redalpine.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage investments are directed toward ICT and health tech startups.
|
Locked | Locked | Locked |
Investor details for Redbiotec
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Redbiotec
Investment portfolio details for Redbiotec
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Redbiotec
Detailed financials for Redbiotec
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Redbiotec Comparisons
Peer comparison for Redbiotec
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Redbiotec
Redbiotec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Adaptive Biotechnologies, Spark Therapeutics and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
Detailed competitors of Redbiotec
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Redbiotec
Complete news archive for Redbiotec
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Redbiotec
Redbiotec was founded in 2006 and raised its 1st funding round 4 years after it was founded.
Redbiotec is headquartered in Schlieren, Switzerland. It is registered at Schlieren, Zurich, Switzerland.
Redbiotec is a funded company, having raised a total of $1.87M across 2 funding rounds to date.
Redbiotec was founded in 2006 as a spin-off from ETH Zurich and operates as a privately held biopharmaceutical company based in Schlieren, Switzerland. Proprietary rePAX co-expression technology is utilized for generating multi-component virus-like particles and protein assemblies. A pipeline of prophylactic VLP vaccines targeting infectious diseases is being advanced, while customized biologics solutions are provided to select partners.
Redbiotec's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Redbiotec offers Key Proteins, Genetic Materials, and BRISPR®tech.
Redbiotec has 1 investor. Key investors include Redalpine.